Cited 18 times in
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김효송 | - |
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2017-10-26T07:29:35Z | - |
dc.date.available | 2017-10-26T07:29:35Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/152102 | - |
dc.description.abstract | PURPOSE: While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. MATERIALS AND METHODS: Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. RESULTS: A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). CONCLUSION: While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents, Immunological/therapeutic use | - |
dc.subject.MESH | Asian Continental Ancestry Group* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Histology* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Receptor, ErbB-2/metabolism* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Stomach Neoplasms/drug therapy* | - |
dc.subject.MESH | Stomach Neoplasms/ethnology* | - |
dc.subject.MESH | Stomach Neoplasms/metabolism | - |
dc.subject.MESH | Stomach Neoplasms/pathology | - |
dc.subject.MESH | Trastuzumab/therapeutic use* | - |
dc.title | A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology | - |
dc.type | Article | - |
dc.publisher.location | Korea | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Jun Ho Yi | - |
dc.contributor.googleauthor | Jung Hun Kang | - |
dc.contributor.googleauthor | In Gyu Hwang | - |
dc.contributor.googleauthor | Hee Kyung Ahn | - |
dc.contributor.googleauthor | Hyun Jin Baek | - |
dc.contributor.googleauthor | Soon Il Lee | - |
dc.contributor.googleauthor | Do Hyoung Lim | - |
dc.contributor.googleauthor | Young-Woong Won | - |
dc.contributor.googleauthor | Jun Ho Ji | - |
dc.contributor.googleauthor | Hyo Song Kim | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Sung Yong Oh | - |
dc.contributor.googleauthor | Kyung Eun Lee | - |
dc.contributor.googleauthor | Taekyu Lim | - |
dc.contributor.googleauthor | Chi Hoon Maeng | - |
dc.contributor.googleauthor | Moon Jin Kim | - |
dc.contributor.googleauthor | Seung Tae Kim | - |
dc.contributor.googleauthor | Jeeyun Lee | - |
dc.contributor.googleauthor | Joon Oh Park | - |
dc.contributor.googleauthor | Young Suk Park | - |
dc.contributor.googleauthor | Ho Yeong Lim | - |
dc.contributor.googleauthor | Won Ki Kang | - |
dc.contributor.googleauthor | Se Hoon Park | - |
dc.identifier.doi | 10.4143/crt.2015.155 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A01202 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.relation.journalsince | 2001~ | - |
dc.identifier.pmid | 26323641 | - |
dc.relation.journalbefore | ~2001 Journal of the Korean Cancer Research Association (대한암학회지) | - |
dc.subject.keyword | ErbB-2 receptor | - |
dc.subject.keyword | Ethnic groups | - |
dc.subject.keyword | Histology | - |
dc.subject.keyword | Stomach neoplasms | - |
dc.subject.keyword | Trastuzumab | - |
dc.contributor.alternativeName | Kim, Hyo Song | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Kim, Hyo Song | - |
dc.citation.volume | 48 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 553 | - |
dc.citation.endPage | 560 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.48(2) : 553-560, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 46882 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.